Skip to main content

Table 1 Representative FDA-approved immunological checkpoint inhibitors

From: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Generic nameTrade nameTargetApplication
pembrolizumabKeytrudaPD-1melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma
nivolumabOpdivoPD-1metastatic small cell lung cancer, metastatic melanoma, metastatic urothelial carcinoma, metastatic colorectal cancer, hepatocellular carcinoma, metastatic nonsmall cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, metastatic squamous cell carcinoma of the head and neck
ipilimumabYervoyCTLA-4advanced renal cell carcinoma, adult and pediatric microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, cutaneous melanoma, unresectable or metastatic melanoma
atezolizumabTecentriqPD-L1urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer
avelumabBavencioPD-L1metastatic Merkel cell carcinoma, locally advanced or metastatic urothelial carcinoma [10]